CRF Health announced an agreement with EuroQol to launch the EQ-5D web system on its TrialMax Web software platform.
CRF Health, a global provider of eCOA solutions for the life sciences industry, announced an agreement with EuroQol to launch the EQ-5D™ web system on its TrialMax Web® software platform. CRF Health has become the first eCOA provider to be granted permission to host the EQ-5D web version for use in clinical trials. CRF Health can now implement the various EQ-5D products across its set of eCOA software solutions, including TrialMax Touch®, TrialMax Slate® and TrialMax Web®. The EQ-5D was developed as a standardized, non-disease specific instrument for describing and valuing health-related quality of life, generating useful insights into overall changes in health.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.